Eisai Co., Ltd. Annual Report 2001 - Eisai GmbH

More documents

Recommendations

Info

12 * 6Structure-Based Drug Design Computational drug design using data on the 3-dimensional structure data of a target molecule. * 7High-Throughput Screening Automated high-speed screening of millions of compounds, utilizing robotics technology. * 8Combinatorial Chemistry Chemical synthesis of a wide variety compounds simultaneously, using many combinations of previously prepared components. * 9KAN Research Institute, Inc. Eisai's 100% subsidiary company founded in 1997, conducting basic research. Once we select drug target molecules, we concentrate efforts on discovering compounds which exhibit pharmacological activity by modulating the function of the target molecules, through the optimum use of SBDD (Structure-Based Drug Design* 6 ), HTS (High-Throughput Screening* 7 ) and combinatorial chemistry* 8 . New Approaches for Drug Discovery Eisai created the original concept “medicinal genetics,” based on our own drug discovery technologies. The concept came from an idea of integrating medicinal chemistry with genomic science and molecular biology. By correlating the pharmacological activity of a compound with the genetic phenotype of model organisms, we can identify the target molecule of a compound. This approach enables us to simultaneously identify both target molecules (genes) and useful compounds which modulate the target molecules. Recently, we have been making steady progress in the discovery of new target molecules and promising compounds for oncology as well as in other therapeutic areas. Moreover, we began a new research effort to identify drug target molecules by applying our comprehensive technologies. We are organizing collaborative relationships with external research institutes, obtaining the latest information and know-how critical to drug discovery. We are also in close collaboration with the KAN Research Institute Inc.* 9 in Kyoto, conducting basic research on neurological and immunological diseases and investigating new technologies for gene hunting. Through the integration of these innovative approaches for drug discovery and prioritizing resource allocation, we are accelerating promising drug discovery programs and vigorously expanding our research capabilities. Eisai Annual Report 2001
REVIEW OF OPERATIONS PHARMACEUTICALS In fiscal 2000, sales in the pharmaceuticals segment, which includes consumer health care products and diagnostic drugs, climbed 23.4% and accounted for 92.4% of consolidated net sales, up from 89.6% in fiscal 1999. Sales were propelled by a sharp increase in sales of Aricept, Aciphex/Pariet and other prescription pharmaceuticals. Prescription Pharmaceuticals Operations in Japan During the period, we continued to place the highest priority on customer satisfaction in all aspects of our pharmaceutical operations, in line with our commitment to meeting the health care needs of patients and improving their quality of life. We recorded stable sales of principal prescription pharmaceuticals, including Aricept, Pariet, Methycobal, the osteoporosis treatment Glakay, the muscle relaxant Myonal and the gastritis/gastric ulcer medication Selbex. We also sought to promote Aricept through direct marketing to physicians by our team of medical representatives (MRs), as well as through active efforts aimed at accelerating time to consultation, diagnosis and, if appropriate, prescription to ensure sufferers of Alzheimer’s disease prompt access to treatment. We also continued to promote sales of Pariet by capitalizing on its reputation as the most effective drug for fast and consistent treatment of gastrointestinal disorders. Eisai Annual Report 2001 13
Page 1 and 2: Human Health Care The script for ou
Page 3 and 4: CONSOLIDATED FINANCIAL HIGHLIGHTS E
Page 5 and 6: In Japan, we are proceeding with de
Page 7 and 8: Fiscal 2001 marks the conclusion of
Page 9 and 10: humanity-based sales activities the
Page 11 and 12: Selected Research Candidates (As of
Page 13: working together to develop antican
Page 17 and 18: Consumer Health Care Products The c
Page 19 and 20: REINFORCING OUR RELATIONSHIP WITH S
Page 21 and 22: FINANCIAL SECTION Contents 20 Finan
Page 23: Net Income Current income taxes for
Page 26 and 27: 24 CONSOLIDATED FINANCIAL STATEMENT
Page 28 and 29: 26 Consolidated Statements of Incom
Page 30 and 31: 28 Consolidated Statements of Cash
Page 32 and 33: 30 (e) Property, plant and equipmen
Page 34 and 35: 32 Proceeds from sales of available
Page 36 and 37: 34 Note 7. Retirement and Pension P
Page 38 and 39: 36 III. Actual lease payments, Depr
Page 40 and 41: 38 Eisai Annual Report 2001 Million
Page 42 and 43: 40 JAPAN AND OVERSEAS OPERATIONS No
Page 44 and 45: 42 MAJOR PRODUCTS Prescription Phar
Page 46 and 47: 44 CORPORATE INFORMATION (As of Mar

Eisai Co., Ltd. Annual Report 2001 - Eisai GmbH

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?